natgillin/translations-raw huggingface dataset:
Nevirapine must not be administered to patients with pre- treatment ASAT or ALAT > 5 ULN until baseline ASAT/ALAT are stabilised < 5 ULN (see section 4.3).
Nevirapin se ne sme dajati bolnikom, ki imajo pred zdravljenjem raven AST ali ALT > 5-kratne zgornje laboratorijske mejne vrednosti, dokler se začetna raven AST/ALT ne stabilizira na < 5-kratno zgornjo mejno vrednost (glejte poglavje 4.3).
Nevirapine must not be administered to patients with pre- treatment ASAT or ALAT > 5 ULN until baseline ASAT/ALAT are stabilised < 5 ULN (see section 4.3).
Nevirapina ne smemo dajati bolnikom, ki imajo pred zdravljenjem raven ASAT ali ALAT > 5-kratne zgornje laboratorijske mejne vrednosti, dokler se začetna raven ASAT/ALAT ne stabilizira na < 5-kratno zgornjo mejno vrednost (glej poglavje 4.3).
Nevirapine must not be administered to patients with pre- treatment ASAT or ALAT > 5 ULN until baseline ASAT/ALAT are stabilised < 5 ULN (see section 4.3).
Nevirapina ne smemo dajati bolnikom, ki imajo pred zdravljenjem raven ASAT ali ALAT > 5-kratne zgornje laboratorijske mejne vrednosti, dokler se začetna raven ASAT/ALAT ne stabilizira na < 5-kratno zgornjo mejno vrednost (glejte poglavje 4.3).
Nevirapine pharmacokinetics in HIV-1 infected adults does not appear to change with age (range 18 - 68 years).
Kaže, da starost (od 18 do 68 let) ne vpliva na nevirapinovo farmakokinetiko pri s HIV-1 okuženih odraslih.
Nevirapine pharmacokinetics in HIV-1 infected adults does not appear to change with age (range 18 – 68 years).
Kaže, da starost (od 18 do 68 let) ne vpliva na nevirapinovo farmakokinetiko pri s HIV-1 okuženih odraslih.
Nevirapine pharmacokinetics in HIV-1 infected adults does not appear to change with age (range 19-68 years) or race (Black, Hispanic, or Caucasian).
Kaže, da se farmakokinetika nevirapina pri s HIV-1 okuženih odraslih s starostjo (v razponu od 19 do 68 let) ne spreminja in je enaka pri različnih rasah (črncih, prebivalcih latinskega izvora, belcih).
Nevirapine Raltegravir
maravirok nevirapin raltegravir
Nevirapine readily crosses the placenta and is found in breast milk.
Nevirapin hitro in z lahkoto prehaja skozi posteljico in se izloča v materino mleko.
Nevirapine Teva is a ‘generic medicine’.
Nevirapine Teva je „generično zdravilo“.
Nevirapine Teva is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infected adults, adolescents, and children of any age (see section 4.2).
Zdravilo Nevirapin Teva je v kombinaciji z drugimi protiretrovirusnimi zdravili indicirano za zdravljenje s HIV-1 okuženih odraslih, mladostnikov in otrok vseh starosti (glejte poglavje 4.4.).
Nevirapine Teva tablets can be taken by:
Tablete Nevirapin Teva lahko jemljejo:
Nevirapine, 200 mg
Nevirapin, 200 mg
Nevirapine, 200 mg BID
200 mg dvakrat na dan
nevirapine.
kombinaciji z nevirapinom.
Nevirapine: compared to historical controls, levels appeared to be
Nevirapin: v primerjavi s prejšnjimi, kontrolnimi vrednostmi so bile ravni nespremenjene.
Nevirapine: exposure: 100% compared with historical data where nevirapine was administered alone.
Nevirapinu: izpostavljenost:  100 % v primerjavi s prejšnjimi podatki, ki so veljali za samostojno uporabo nevirapina.
Nevirapine: plasma levels: ↑1.15-1.28- fold compared to historical controls
Nevirapin: ravni v plazmi: ↑ 1,15–1,28- krat v primerjavi z zgodovinskimi kontrolami
Nevirapine: The effect of nevirapine on other protease inhibitors and the limited evidence available suggest that nevirapine may decrease the serum concentrations of amprenavir.
Nevirapin: Učinek nevirapina na druge zaviralce proteaze in omejenost razpoložljivih dokazov dopuščata možnost, da lahko nevirapin zniža serumsko koncentracijo amprenavirja.
Nevirapine:  (CYP3A induction)
Nevirapin:  (indukcija CYP3A)
Nevirapinemust not be restarted following severe hepatic, skin or hypersensitivity reactions (see section 4.3).
Po hudih jetrnih, kožnih ali preobčutljivostnih reakcijah nevirapina ne smemo ponovno uvesti (glejte poglavje 4.3).
New and unused OptiSet: a dose of 8 units is already preset by the manufacturer for the first safety test.
Nov, še neuporabljen OptiSet: odmerek 8 enot za prvi varnostni preizkus je nastavil že izdelovalec.
New and worsening congestive heart failure has been reported with TNF blockers, including Simponi.
Pri uporabi zaviralcev TNF, vključno z zdravilom Simponi, so poročali o novem pojavu ali poslabšanju kongestivnega srčnega popuščanja.
New Born
novorojenec
New born calves.
Novorojena teleta
New born infant exposed to antipsychotics (including olanzapine) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery.
Pri novorojenčkih, ki so bili med tretjim trimesečjem nosečnosti izpostavljeni antipsihotikom (vključno z olanzapinom), obstaja tveganje za pojav neželenih učinkov, vključno z ekstrapiramidnimi in/ali odtegnitvenimi simptomi, katerih jakost in čas trajanja po porodu sta lahko različna.
New cardiovascular events (primary endpoint) were prevented, with relative risk reductions of 22% (CI: 8.6, 33.4), 32% (CI: 12.8,
Nove srčnožilne dogodke (primarni opazovani dogodek) so preprečeli z zmanjšanjem relativnega tveganja: 22
New cardiovascular events (primary endpoint) were prevented, with relative risk reductions of 22% (CI: 8.6, 33.4), 32% (CI: 12.8,
Nove srčnožilne dogodke (primarni opazovani dogodek) so preprečeli z zmanjšanjem relativnega tveganja: 22 % (IZ: 8,6, 33,4), 32 % (IZ: 12,8, 46,4), 4 % (IZ: -26,9, 26,7), 6 % (IZ: -33,5,
New cardiovascular events (primary endpoint) were prevented, with relative risk reductions of 22% (CI: 8.6, 33.4), 32% (CI: 12.8,
Nove srčnožilne dogodke (primarni opazovani dogodek) so preprečili z zmanjšanjem relativnega tveganja: 22 % (IZ: 8,6, 33,4), 32 % (IZ: 12,8, 46,4), 4 % (IZ: -26,9, 26,7), 6 % (IZ: -33,5,
New cardiovascular events (primary endpoint) were prevented, with relative risk reductions of 22% (CI: 8.6, 33.4), 32% (CI: 12.8, 46.4), 4% (CI: -26.9, 26.7), 6% (CI: -33.5, 34.3) and 14% (CI: -31.6, 44.2), during the 0-1,
Nove srčnožilne dogodke (primarni opazovani dogodek) so preprečeli z zmanjšanjem relativnega tveganja: 22 % (IZ: 8,6, 33,4), 32 % (IZ: 12,8, 46,4), 4 % (IZ: -26,9, 26,7), 6 % (IZ: -33,5,
New cardiovascular events (primary endpoint) were prevented, with relative risk reductions of 22% (CI: 8.6, 33.4), 32% (CI: 12.8, 46.4), 4% (CI: -26.9, 26.7), 6% (CI: -33.5, 34.3) and 14% (CI: -31.6, 44.2), during the 0-1,
Nove srčnožilne dogodke (primarni opazovani dogodek) so preprečili z zmanjšanjem relativnega tveganja v višini 22 % (IZ: 8,6; 33,4), 32 % (IZ: 12,8; 46,4), 4 % (IZ: -26,9;
New cardiovascular events (primary endpoint) were prevented, with relative risk reductions of 22% (CI: 8.6, 33.4), 32% (CI: 12.8, 46.4), 4% (CI: -26.9, 26.7), 6% (CI: -33.5, 34.3) and 14% (CI: -31.6, 44.2), during the 0-1, 1-3,
Nove srčnožilne dogodke (primarni opazovani dogodek) so preprečili z zmanjšanjem relativnega tveganja: 22 % (IZ: 8,6, 33,4), 32 % (IZ: 12,8, 46,4), 4 % (IZ: -26,9, 26,7),
New cardiovascular events (primary endpoint) were prevented, with relative risk reductions of 22% (CI: 8.6, 33.4), 32% (CI: 12.8, 46.4), 4% (CI: -26.9, 26.7), 6% (CI: -33.5, 34.3) and 14% (CI: -31.6, 44.2), during the 0-1, 1-3,
Nove srčnožilne dogodke (primarni opazovani dogodek) so preprečili z zmanjšanjem relativnega tveganja: 22 % (IZ: 8,6, 33,4), 32 % (IZ: 12,8, 46,4), 4 % (IZ: -26,9, 26,7), 6 % (IZ: -33,5,
New cutaneous or subcutaneous lumps
Pojav novih kožnih ali podkožnih vozličev
New Dialysis Event-Free Status, n (%)
stanje brez dogodka nove dialize, n (%)
New ENF
Prvič ENF
New events (all grade 1 or grade 2) occurred generally early during ONIVYDE treatment, with only 2 out of 10 patients noted with events after the fifth dose.
Novi neželeni učinki (vsi 1. ali 2. stopnje) so se v splošnem pojavili zgodaj med zdravljenjem z zdravilom ONIVYDE, le 2 bolnika od 10 sta neželene učinke doživela po petem odmerku.
New information for use:
Nove informacije za uporabo:
New injections should be given at least 2.5 cm away from an old site.
Novo injekcijo je treba dati vsaj 2,5 cm oddaljeno od prejšnjega mesta injiciranja.
New injections should be given at least 2.5 cm from the old site and never into areas where the skin is red, bruised, tender, or hard.
Nove injekcije damo najmanj 2,5 cm oddaljeno od prejšnjega mesta injiciranja in nikoli na področja, kjer je koža pordela, ima modrice, je nežna ali trda.
New injections should be given at least 2.5 cm from the old site on healthy skin and never into areas where the skin is red, bruised, tender, or hard.
Nove injekcije damo najmanj 2,5 cm oddaljeno od prejšnjega mesta injiciranja na zdravo kožo in nikoli na področja, kjer je koža pordela, ima modrice, je nežna ali trda.
New injections should be given at least 2.5 cm from the previous site and never into areas where the site is tender, bruised, red, or hardened.
Nove injekcije morate dati vsaj 2,5 cm od prejšnjega mesta injiciranja in nikoli na predel, ki je občutljiv, poškodovan, pordel ali otrdel.
New Jersey NJ 08876
New Jersey NJ 08876 ZDA
New Jersey USA
New Jersey ZDA
New malignancies
Novi malignomi
New malignancies, cutaneous and non-cutaneous, can occur when dabrafenib is used as monotherapy or in combination with trametinib.
Pri uporabi dabrafeniba v monoterapiji ali v kombinaciji s trametinibom lahko pride do razvoja novih malignomov, tako kožnih kot nekožnih.
New malignancies, cutaneous and non-cutaneous, can occur when trametinib is used in combination with dabrafenib.
Pri uporabi trametiniba v kombinaciji z dabrafenibom lahko pride do razvoja novih malignomov, tako kožnih kot nekožnih.
New melanoma
nov melanom
new onset diabetes mellitus or hyperglycaemia, or exacerbation of pre-existing diabetes mellitus, hypertriglyceridaemia, hypercholesterolaemia.
pojav sladkorne bolezni ali hiperglikemije ali poslabšanje že obstoječe sladkorne bolezni, hipertrigliceridemija, hiperholesterolemija
New onset of diabetes mellitus, hyperglycaemia or exacerbations of existing diabetes mellitus have been reported in patients receiving antiretroviral therapy, including protease inhibitors.
Pri bolnikih, ki so prejemali protiretrovirusna zdravila, vključno zaviralce proteaz, so poročali o pojavu sladkorne bolezni, o hiperglikemiji ali o poslabšanju obstoječe sladkorne bolezni.
New onset of migraine-type headache Endometrial hyperplasia and carcinoma
Hiperplazija endometrija in karcinom
new onset or worsening of psoriasis
pojav ali poslabšanje psoriaze
new onset or worsening of psoriasis;
pojav ali poslabšanje psoriaze;
New onset or worsening psoriasis including pustular psoriasis (primarily palm & soles), urticaria, rash, pruritus, hyperhidrosis, dry skin, fungal dermatitis, eczema, alopecia.
pogosti: novo nastala in poslabšana psoriaza, vključno s pustulozno psoriazo (predvsem na dlaneh in podplatih), urtikarija, izpuščaj, pruritus, hiperhidroza, suha koža, glivični dermatitis, ekcem, alopecija
New or progressive dyspnoea, cough, and fever should prompt interruption of ONIVYDE treatment, pending diagnostic evaluation.
Dokler ni opravljena diagnostična ocena, je treba ob pojavu nove ali napredovale dispneje, kašlja in povišane telesne temperature zdravljenje z zdravilom ONIVYDE začasno prekiniti.
New or reactivated (recurring) cytomegalovirus infections and reactivated hepatitis B virus infections have been uncommonly reported.
Občasno so poročali o novih ali ponovnih (ponavljajočih se) okužbah s citomegalovirusom in ponovnih okužbah z virusom hepatitisa B.
New or reactivated (recurring) cytomegalovirus infections and reactivated hepatitis B virus infections have been uncommonly reported.
Občasno so poročali o novih ali reaktiviranih (ponovljenih) okužbah s citomegalovirusom in o reaktiviranih okužbah z virusom hepatitisa B.
New or worsening cough with or without mucus, fever, chest pain, trouble breathing or shortness of breath (potential signs of lung problems)
novonastali kašelj ali poslabšanje že prej prisotnega kašlja z izmečkom ali brez izmečka, zvišana telesna temperatura, bolečine v prsih, oteženo dihanje ali zadihanost (to so lahko znaki težav s pljuči),
New or worsening heart failure, slow heart rate
novo nastalo srčno popuščanje ali poslabšanje srčnega popuščanja, počasen srčni utrip
New or worsening heart failure, slow heart rate
novo nastalo srčno popuščanje ali poslabšanje srčnega popuščanja, počasen srčni utrip,
new or worsening pain in the belly, with or without nausea and vomiting; pain may begin soon after you start Truberzi.
nova ali poslabšana bolečina v trebuhu, s siljenjem na bruhanje in bruhanjem ali brez njiju; bolečina lahko nastopi kmalu po začetku jemanja zdravila Truberzi.
New pen (orange window)
New peresnik (oranžno okence)
New Pen Setup is now done.
Priprava novega peresnika je sedaj zaključena.
NEW PEN SETUP – DO THIS ONE TIME ONLY
PRIPRAVA NOVEGA INJEKCIJSKEGA PERESNIKA – PRIPRAVITE SAMO ENKRAT
New pre-filled pen.
Nov napolnjen injekcijski peresnik.
New primary melanoma
nov primarni melanom
New primary melanoma was reported in patients receiving trametinib in combination with dabrafenib.
Pri bolnikih, zdravljenih s trametinibom v kombinaciji z dabrafenibom, so poročali o pojavu novega primarnega melanoma.
New primary melanomas have been reported in clinical trials with dabrafenib as monotherapy and in combination with trametinib.
V kliničnih preskušanjih dabrafeniba v monoterapiji in v kombinaciji s trametinibom so bili opisani novi primarni melanomi.
New radiographic vertebral fracture in patients without any prevalent fracture at baseline Percentage of patients with new fracture
Novi rentgenski vretenčni zlomi pri bolnicah brez prevladujočega zloma v izhodišču Odstotni delež bolnic z novim zlomom
New radiographic vertebral fractures Percentage of patients with new fracture
Novi rentgenski vretenčni zlomi Odstotni delež bolnic z novim zlomom
new wart
novo bradavico
new wart
novo bradavico,
newborn
novoro- jenček
Newborn (5 kg)
Novorojenč ki (5 kg)
newborn babies may show the following: agitation, increase or decreases in muscle tone, tremor, sleepiness, breathing or feeding problems
pri novorojenčkih se lahko pojavi naslednje: agitacija (nemir), povečana ali zmanjšana mišična napetost, tresenje, zaspanost, težave z dihanjem ali motnje hranjenja
newborn babies whose mothers are carriers of the virus;
pri novorojenčkih, katerih matere so prenašalke virusa;
newborn babies, babies, children, teenagers 0-17 years and adults with high blood pressure in the lungs, connected with heart surgery.
novorojenčkov, otrok in mladostnikov, starih od 0 do 17 let, ter odraslih z visokim krvnim tlakom v pljučih, povezanim s srčnim kirurškim posegom.
Newborn infants of mothers who have either not had chickenpox or have not been vaccinated against chickenpox.
Novorojenčki mater, ki še niso imele noric ali niso bile cepljene proti noricam.
Newborn infants, infants and toddlers, children and adolescents, ages 0-17 years
Novorojenčki, otroci in mladostniki, stari od 0 do 17 let
Newborns, infants and pregnant women should not be in the same room while you are inhaling Ventavis.
Novorojenci, dojenčki in nosečnice ne smejo biti v istem prostoru, medtem ko inhalirate zdravilo Ventavis.
Newbridge County Kildare Ireland
Little Connell Newbridge County Kildare Irska
Newbury, Berkshire, RG14 1JG United Kingdom
Newbury, Berkshire, RG14 1JG Velika Britanija
Newcastle disease and Marek’s disease vaccine (live recombinant)
cepivo proti bolezni Newcastle in Marekovi bolezni (živo, rekombinantno)
Newcastle upon Tyne NE3 3TT – UK United Kingdom
Newcastle upon Tyne NE3 3TT - UK Velika Britanija
Newcastle upon Tyne NE3 3TT – UK United Kingdom‌
Newcastle upon Tyne NE3 3TT - UK Velika Britanija
Newcastle Upon Tyne, Tyne & Wear NE3 3TT - UK, United Kingdom and/or
Newcastle Upon Tyne, Tyne& Wear NE3 3TT – UK, Velika Britanija in/ali
Newcastle Upon Tyne, Tyne & Wear NE3 3TT - UK, United Kingdom or
Newcastle Upon Tyne, Tyne& Wear NE3 3TT – UK, Velika Britanija ali
Newly diagnosed
Novoodkriti
Newly diagnosed adult patients
novo diagnosticirani odrasli bolniki
Newly diagnosed adult patients
Odrasli bolniki z na novo diagnosticirano boleznijo
Newly diagnosed adult patients should be started on 1/6 to 1/4 of the targeted maintenance dose of PROCYSBI.
Pri odraslih bolnikih z na novo diagnosticirano boleznijo je treba zdravljenje začeti z 1/6 do 1/4 ciljnega vzdrževalnega odmerka zdravila PROCYSBI.
Newly diagnosed cardiac dysfunction occurred in 13 (20.6%) deferoxamine-treated patients and in 2 (4.3%) Ferriprox-treated patients who were cardiac disease-free at the first assessment (p=0.013).
Do na novo ugotovljene srčne disfunkcije je prišlo pri 13 (20,6 %) pacientih, ki so jih zdravili z deferoksaminom in pri 2 (4,3 %) pacientih, ki so jemali Ferriprox in niso imeli srčne bolezni pri prvem ocenjevanju (p = 0,013).
Newly diagnosed chronic phase CML at 300 mg twice daily
novo odkrita KML v kronični fazi pri odmerku 300 mg dvakrat dnevno
Newly diagnosed multiple myeloma
Novo diagnosticirani diseminirani plazmocitom
Newly diagnosed multiple myeloma in patients treated with lenalidomide in combination with low dose dexamethasone
Novo diagnosticirani diseminirani plazmocitom pri bolnikih, zdravljenih z lenalidomidom v kombinaciji z deksametazonom v majhnem odmerku
Newly diagnosed multiple myeloma in patients treated with lenalidomide in combination with melphalan and prednisone
Novo diagnosticirani diseminirani plazmocitom pri bolnikih, zdravljenih z lenalidomidom v kombinaciji z melfalanom in prednizonom
Newly diagnosed multiple myeloma patients
Bolniki z novo diagnosticiranim diseminiranim plazmocitomom
Newly diagnosed multiple myeloma patients treated with lenalidomide in combination with low dose dexamethasone
Bolniki z novo diagnosticiranim diseminiranim plazmocitomom, zdravljeni z lenalidomidom v kombinaciji z deksametazonom v majhnem odmerku
Newly diagnosed multiple myeloma patients treated with lenalidomide in combination with melphalan and prednisone
Bolniki z novo diagnosticiranim diseminiranim plazmocitomom, zdravljeni z lenalidomidom v kombinaciji z melfalanom in prednizonom
Newly diagnosed paediatric population
Pediatrična populacija z na novo diagnosticirano boleznijo
Newly observed adverse reactions: ecchymosis, petechia, abnormal white blood cells, thromboplastin decreased, abnormal erythrocytes, dehydration, increased gonadotrophic luteinizing hormone, weight loss, increased alkaline phosphatase, increased creatinine phosphokinase, lipase increased, hypercalcaemia, migraine, peripheral neuritis, paraesthesia, hypertonia, confusion, anxiety, emotional lability, somnolence, decreased libido, nervousness, night blindness, nystagmus, lacrimation disorder, tinnitus, taste perversion, chest pain, arrhythmia, peripheral vascular disorder, generalized oedema, haemoptysis, dyspnoea, increased cough, sinusitis, pharyngitis, dysphagia, mouth ulceration, oral moniliasis, stomatitis, dyspepsia, thirst, abnormal stools, eructation, vesicobullous rash, maculopapular rash, leg cramps, haematuria, flu syndrome, pelvic pain, and body odour.
Novo opaženi neželeni učinki so bili: ekhimoza, petehije, nenormalni levkociti, znižan tromboplastin, nenormalni eritrociti, dehidracija, zvišan gonadotropni luteinizirajoči hormon, izguba teže, zvišana alkalna fosfataza, zvišana kreatinin-fosfokinaza, zvišana lipaza, hiperkalcemija, migrena, periferni nevritis, parestezija, hipertonija, zmedenost, strah, emocionalna labilnost, zaspanost, zmanjšan libido, nervoznost, nočna slepota, nistagmus, motnje solzenja, tinitus, motnje okušanja, bolečine v prsih, aritmija, periferne žilne bolezni, generaliziran edem, hemoptiza, dispneja, povečan kašelj, sinusitis, faringitis, disfagija, razjede v ustih, oralna moniliaza, stomatitis, dispepsija, žeja, nenormalno blato, kolcanje, vezikularni izpuščaji, makulopapulozni izpuščaji, krči v nogah, hematurija, sindrom influence, medenične bolečine in telesni vonj.
Newly reported adverse drug reactions, which occurred more frequently in the sildenafil/ epoprostenol group, were ocular hyperaemia, vision blurred, nasal congestion, night sweats, back pain and dry mouth.
Novo opisani neželeni učinki, pogostejši v skupini, ki je dobivala sildenafil/epoprostenol, so bili očesna hiperemija, zamegljen vid, zamašenost nosu, nočno znojenje, bolečine v hrbtu in suha usta.
Newly-diagnosed glioblastoma multiforme
Na novo diagnosticirani multiformni glioblastom
Newly-diagnosed glioblastoma multiforme
Novo diagnosticirani multiformni glioblastom
NexGard 11 mg chewable tablets for dogs (2–4 kg) NexGard 28 mg chewable tablets for dogs (>4–10 kg) NexGard 68 mg chewable tablets for dogs (>10–25 kg) NexGard 136 mg chewable tablets for dogs (>25–50 kg) Afoxolaner
NexGard 11 mg žvečljive tablete za pse 2–4 kg NexGard 28 mg žvečljive tablete za pse >4–10 kg NexGard 68 mg žvečljive tablete za pse >10–25 kg NexGard 136 mg žvečljive tablete za pse >25–50 kg
NexGard 11 mg chewable tablets for dogs 2–4 kg NexGard 28 mg chewable tablets for dogs >4–10 kg NexGard 68 mg chewable tablets for dogs >10–25 kg NexGard 136 mg chewable tablets for dogs >25–50 kg
NexGard 11 mg žvečljive tablete za pse 2 ̶ 4 kg NexGard 28 mg žvečljive tablete za pse > 4 ̶ 10 kg  NexGard 68 mg žvečljive tablete za pse >10 ̶ 25 kg NexGard 136 mg žvečljive tablete za pse >25 ̶ 50 kg
NexGard 11 mg chewable tablets for dogs 2–4 kg NexGard 28 mg chewable tablets for dogs >4–10 kg NexGard 68 mg chewable tablets for dogs >10–25 kg NexGard 136 mg chewable tablets for dogs >25–50 kg
NexGard 11 mg žvečljive tablete za pse 2–4 kg NexGard 28 mg žvečljive tablete za pse >4–10 kg NexGard 68 mg žvečljive tablete za pse >10–25 kg NexGard 136 mg žvečljive tablete za pse >25–50 kg
NexGard is a veterinary medicine that contains the active substance afoxolaner.
NexGard je zdravilo za uporabo v veterinarski medicini, ki vsebuje zdravilno učinkovino afoksolaner.
NexGard is given as a tablet of the appropriate strength for the dog’s bodyweight.
Zdravilo NexGard se daje kot tableta, katere jakost ustreza telesni masi psa.
NexGard is used to treat flea and tick infestations in dogs.
Zdravilo NexGard se uporablja za zdravljenje infestacij z bolhami in klopi pri psih.
NexGard kills fleas within 8 hours and ticks within 48 hours.
Zdravilo NexGard bolhe ubije v 8 urah, klope pa v 48 urah.
NexGard kills fleas within 8 hours and ticks within 48h.
Nexgard ubije bolhe v največ 8 urah in klope najkasneje v 48 urah.
NexGard reduced the number of fleas and ticks by at least 98% and was at least as effective as pyriprole.
Zdravilo NexGard je zmanjšalo število bolh in klopov za najmanj 98 % in je bilo vsaj tako učinkovito kot piriprol.
NEXGARD SPECTRA 9 mg / 2 mg chewable tablets for dogs 2–3.5 kg NEXGARD SPECTRA 19 mg / 4 mg chewable tablets for dogs >3.5–7.5 kg NEXGARD SPECTRA 38 mg / 8 mg chewable tablets for dogs >7.5–15 kg NEXGARD SPECTRA 75 mg / 15 mg chewable tablets for dogs >15–30 kg NEXGARD SPECTRA 150 mg / 30 mg chewable tablets for dogs >30–60 kg
NEXGARD SPECTRA 9 mg/ 2 mg žvečljive tablete za pse 2–3,5 kg NEXGARD SPECTRA 19mg/ 4 mg žvečljive tablete za pse >3,5–7,5 kg NEXGARD SPECTRA 38 mg/ 8 mg žvečljive tablete za pse >7,5 –15 kg NEXGARD SPECTRA 75 mg/ 15 mg žvečljive tablete za pse >15–30 kg NEXGARD SPECTRA 150 mg/ 30 mg žvečljive tablete za pse >30–60 kg
NEXGARD SPECTRA 9 mg / 2 mg chewable tablets for dogs 2–3.5 kg NEXGARD SPECTRA 19 mg / 4 mg chewable tablets for dogs >3.5–7.5 kg NEXGARD SPECTRA 38 mg / 8 mg chewable tablets for dogs >7.5–15 kg NEXGARD SPECTRA 75 mg / 15 mg chewable tablets for dogs >15–30 kg NEXGARD SPECTRA 150 mg / 30 mg chewable tablets for dogs >30–60 kg
NEXGARD SPECTRA 9 mg/ 2 mg žvečljive tablete za pse 2–3,5 kg NEXGARD SPECTRA 19mg/ 4 mg žvečljive tablete za pse >3,5–7,5 kg NEXGARD SPECTRA 38 mg/ 8 mg žvečljive tablete za pse >7,5–15 kg NEXGARD SPECTRA 75 mg/ 15 mg žvečljive tablete za pse >15–30 kg NEXGARD SPECTRA 150 mg/ 30 mg žvečljive tablete za pse >30–60 kg